Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) was the target of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 57,300 shares, a decline of 68.0% from the November 30th total of 179,100 shares. Based on an average daily trading volume, of 798,300 shares, the short-interest ratio is currently 0.1 days. Currently, 1.6% of the company’s shares are short sold.

Onconetix Stock Performance

Onconetix stock traded up $0.02 during trading hours on Thursday, reaching $0.36. 742,944 shares of the company’s stock were exchanged, compared to its average volume of 325,868. The firm’s 50 day simple moving average is $1.80 and its 200 day simple moving average is $4.33. Onconetix has a twelve month low of $0.32 and a twelve month high of $21.40.

Hedge Funds Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Onconetix, Inc. (NASDAQ:ONCO) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 1.37% of Onconetix as of its most recent SEC filing. Institutional investors own 23.89% of the company’s stock.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.